C. Robert Horsburgh, MD
Professor, Global Health
Biography
Dr. Horsburgh has 30 years of experience in public health and medicine. He currently holds faculty positions in the Departments of Epidemiology, Biostatistics, Global Health and Medicine. Dr. Horsburgh teaches courses in the Epidemiology of AIDS, the Epidemiology of Tuberculosis and Vaccine Epidemiology. His research focuses on tuberculosis, nontuberculous mycobacterial infections and opportunistic infections in AIDS. Currently, he is involved in research in Brazil, India, South Africa, Tanzania, Vietnam and the Philippines. He is a member of the Board of Directors of the International Union Against Tuberculosis and Lung Disease (IUATLD) and Chairman of the Steering Committee of RESIST-TB, an international organization dedicated to improving MDR-TB treatment through Clinical Trials and dissemination of best practices (www.resisttb.org).
Other Positions
- Professor, Epidemiology, Boston University School of Public Health
- Professor, Infectious Diseases, Medicine, Boston University Chobanian & Avedisian School of Medicine
- Professor, Biostatistics, Boston University School of Public Health
- Boston Medical Center
Education
- Case Western Reserve University, MD
- Yale University, MS
- Princeton University, AB
Publications
- Published on 2/20/2025
Tzelios CA, Malatesta S, Carney T, White LF, Weber SE, Thomson S, Theron D, Myers B, Parry CDH, Warren RM, Horsburgh CR, Farhat MR, Jacobson KR. Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort Analysis. Clin Infect Dis. 2025 Feb 20. PMID: 39973802.
Read at: PubMed - Published on 2/10/2025
Menzies NA, Marks SM, Hsieh YL, Swartwood NA, Beeler Asay GR, Skarbinski J, Horsburgh CR, Cohen T. Contribution of Post-TB Sequelae to Life-Years Lost from TB Disease in the United States, 2015-2019. Am J Respir Crit Care Med. 2025 Feb 10. PMID: 39928299.
Read at: PubMed - Published on 2/7/2025
Li Y, Marks SM, Beeler Asay GR, Winston CA, Pepin D, McClure S, Swartwood NA, Cohen T, Horsburgh CR, Salomon JA, Menzies NA. Effectiveness and Cost-Effectiveness of Expanded Targeted Testing and Treatment of Latent Tuberculosis Infection Among the Medicare Population in 2022. Ann Intern Med. 2025 Apr; 178(4):479-489. PMID: 39918348.
Read at: PubMed - Published on 2/3/2025
Chen C, Xue H, Horsburgh CR, Amour M, Hatherill M, Tameris M, von Reyn CF, Rees C, Shen Y, McShane H, García-Basteiro AL, Liu D, Wang Y, Nathavitharana RR, Graviss EA, Shao Y, Liu Q, Lu W, Zhu L, Martinez L. Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United States. Chest. 2025 Feb 03. PMID: 39909102.
Read at: PubMed - Published on 11/26/2024
Burman W, Luczynski P, Horsburgh CR, Phillips PPJ, Johnston J. Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review. Lancet Infect Dis. 2025 Feb; 25(2):e86-e98. PMID: 39612926.
Read at: PubMed - Published on 11/15/2024
Rosen LV, Thielking AM, Dugdale CM, Montepiedra G, Kalk E, Kim S, LaCourse SM, Mathad JS, Freedberg KA, Horsburgh CR, Paltiel AD, Wood R, Ciaranello AL, Reddy KP. Tuberculosis Preventive Treatment for Pregnant People With Human Immunodeficiency Virus in South Africa: A Modeling Analysis of Clinical Benefits and Risks. Clin Infect Dis. 2024 Nov 15. PMID: 39544107.
Read at: PubMed - Published on 10/31/2024
von Reyn CF, Arbeit RD, Horsburgh CR. HIV-Associated Tuberculosis. N Engl J Med. 2024 Oct 31; 391(17):1662-1663. PMID: 39476355.
Read at: PubMed - Published on 10/28/2024
Burman W, Horsburgh CR, Johnston J. Predictable excess hepatotoxicity in the SimpliciTB trial. Lancet Infect Dis. 2024 Dec; 24(12):e727. PMID: 39481423.
Read at: PubMed - Published on 10/18/2024
Swartwood NA, Cohen T, Marks SM, Hill AN, Asay GRB, Self J, Feng PI, Horsburgh CR, Salomon JA, Menzies NA. Effects of the COVID-19 pandemic on TB outcomes in the United States: a Bayesian analysis. medRxiv. 2024 Oct 18. PMID: 39484245.
Read at: PubMed - Published on 10/15/2024
Prakash Babu S, Ezhumalai K, Raghupathy K, Karoly M, Chinnakali P, Gupte N, Paradkar M, Devarajan A, Dhanasekaran M, Thiruvengadam K, Dauphinais MR, Gupte AN, Shivakumar SB, Thangakunam B, Christopher DJ, Viswanathan V, Mave V, Gaikwad S, Kinikar A, Kornfeld H, Horsburgh CR, Chandrasekaran P, Hochberg NS, Salgame P, Gupta A, Roy G, Ellner J, Sinha P, Sarkar S. Factors Associated With Unfavorable Treatment Outcomes Among Persons With Pulmonary Tuberculosis: A Multicentric Prospective Cohort Study From India. Clin Infect Dis. 2024 Oct 15; 79(4):1034-1038. PMID: 38991034.
Read at: PubMed
View 350 more publications: View full profile at BUMC